Covid-19 roundup: Pfizer/BioNTech shot just as effective in real world, study says, as pair preps variant booster shots
The first real-world evidence for Pfizer/BioNTech’s Covid-19 vaccine is in, and there’s a lot for the companies to like.
Two months into the vaccine’s rollout in Israel, researchers from the country’s Clalit Research Institute have published the first study to be peer-reviewed over whether or not the shot is effective outside a controlled clinical trial setting. They have found the two-dose vaccine regimen cut symptomatic Covid-19 cases by 94% across all age groups and severe cases by almost as much.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
